Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
Luis Arias,1–3 Francisco Gómez-Ulla,2–4 José M Ruiz-Moreno2,3,51Ophthalmology Department, Bellvitge University Hospital, C/Feixa Llarga, L’Hospitalet de Llobregat, Barcelona, 2Spanish Vitreoretinal Society (SERV), C/Xosé Chao Rego, Santi...
Saved in:
Main Authors: | Arias L, Gómez-Ulla F, Ruiz-Moreno JM |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/542781159ffc4438b11c5d1aba783e07 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
by: Maruyama-Inoue M, et al.
Published: (2019) -
Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
by: Takahashi K, et al.
Published: (2018) -
Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
by: Gallemore RP, et al.
Published: (2017) -
Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017) -
Evaluation of peripheral fundus autofluorescence in eyes with wet age-related macular degeneration
by: Suetsugu T, et al.
Published: (2016)